title: Progression of myopic maculopathy after treatment of choroidal neovascularization.
abstract: OBJECTIVE
  To evaluate the long-term progression of myopic maculopathy and functional outcome after treatment of myopic choroidal neovascularization (CNV) with photodynamic therapy (PDT) and/or intravitreal ranibizumab (IVR).
  
  
  METHODS
  Retrospective study with a cross-sectional evaluation. Eyes were assigned to 4 groups (PDT, IVR, PDT + IVR, dry myopic maculopathy) and evaluated with best-corrected visual acuity, color fundus photography and spectral-domain optical coherence tomography. Chorioretinal atrophy progression was quantified.
  
  
  RESULTS
  Fifty-four eyes were included with a mean follow-up of 80.6 ± 28.0 months. The prevalence of diffuse, patchy and macular atrophy increased during the follow-up, in contrast with tessellated fundus, lacquer cracks and active CNV. Progression of macular atrophy was significant in the 3 treatment groups (p < 0.05) and predictive of visual acuity. It depended on age, degree of myopia and presence of staphyloma, but not on the type of treatment.
  
  
  CONCLUSIONS
  The long-term functional outcome of eyes with myopic CNV is more dependent on the progression of macular atrophy, and not on the type of treatment.
authors.affiliation: Medical Retina Unit, Ophthalmology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
authors.forename: Cláudia L
authors.initials: CL
authors.lastname: Farinha
authors.forename: Alda S
authors.initials: AS
authors.lastname: Baltar
authors.forename: Sandrina G
authors.initials: SG
authors.lastname: Nunes
authors.forename: João P
authors.initials: JP
authors.lastname: Figueira
authors.forename: Isabel A
authors.initials: IA
authors.lastname: Pires
authors.forename: Maria L
authors.initials: ML
authors.lastname: Cachulo
authors.forename: Rufino M
authors.initials: RM
authors.lastname: Silva
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D003317:Corneal Dystrophies, Hereditary / Q000175:diagnosis* / Q000503:physiopathology; D003430:Cross-Sectional Studies; D018450:Disease Progression; D004338:Drug Combinations; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D000069579:Ranibizumab; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004338:Drug Combinations; D017319:Photosensitizing Agents; D011166:Porphyrins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000077362:Verteporfin; D000069579:Ranibizumab